Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

CEO

Douglas S. Ingram

CEODouglas S. Ingram

Employees

835

Employees835

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

835

Employees835

SRPT Key Statistics

Market cap

1.68B

Market cap1.68B

Price-Earnings ratio

-16.81

Price-Earnings ratio-16.81

Dividend yield

—

Dividend yield—

Average volume

3.28M

Average volume3.28M

High today

$16.37

High today$16.37

Low today

$15.92

Low today$15.92

Open price

$16.20

Open price$16.20

Volume

909.59K

Volume909.59K

52 Week high

$25.32

52 Week high$25.32

52 Week low

$10.42

52 Week low$10.42

Stock Snapshot

The current Sarepta Therapeutics(SRPT) stock price is $15.95, with a market capitalization of 1.68B. The stock trades at a price-to-earnings (P/E) ratio of -16.81.

As of 2026-07-22, Sarepta Therapeutics(SRPT) stock has fluctuated between $15.92 and $16.37. The current price stands at $15.95, placing the stock +0.2% above today's low and -2.6% off the high.

The Sarepta Therapeutics(SRPT)'s current trading volume is 909.59K, compared to an average daily volume of 3.28M.

In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $25.32 and a 52-week low of $10.42.

SRPT News

TipRanks 19h

Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Sell rating on Sarepta Therapeutics, with a price target of $13.00. Claim 55% Off TipRa...

TipRanks 1d

Citi sees intensifying competition for Sarepta from Dyne Therapeutics

Citi sees increased competition for Sarepta (SRPT) after the FDA accepted Dyne Therapeutics’ (DYN) application for z-rostudirsen in Duchenne muscular dystrophy....

Investor's Business Daily 2d

Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits? - Investor's Business Daily

...

Analyst ratings

46%

of 26 ratings

Buy

30.8%

Hold

46.2%

Sell

23.1%

More SRPT News

Simply Wall St 4d

Has Sarepta Therapeutics Fallen Below Fair Value After FDA Progress?

Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed...

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.